KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Gilead Sciences (GILD) Operating Expenses (2016 - 2026)

Gilead Sciences filings provide 17 years of Operating Expenses readings, the most recent being $5.9 billion for Q4 2025.

  • On a quarterly basis, Operating Expenses rose 16.1% to $5.9 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $19.4 billion, a 28.31% decrease, with the full-year FY2025 number at $19.4 billion, down 28.31% from a year prior.
  • Operating Expenses hit $5.9 billion in Q4 2025 for Gilead Sciences, up from $4.4 billion in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $11.0 billion in Q1 2024 to a low of $3.5 billion in Q1 2021.
  • Median Operating Expenses over the past 5 years was $4.6 billion (2023), compared with a mean of $5.2 billion.
  • Biggest five-year swings in Operating Expenses: surged 136.88% in 2024 and later tumbled 59.76% in 2025.
  • Gilead Sciences' Operating Expenses stood at $6.3 billion in 2021, then decreased by 18.75% to $5.1 billion in 2022, then increased by 7.42% to $5.5 billion in 2023, then dropped by 7.0% to $5.1 billion in 2024, then grew by 16.1% to $5.9 billion in 2025.
  • The last three reported values for Operating Expenses were $5.9 billion (Q4 2025), $4.4 billion (Q3 2025), and $4.6 billion (Q2 2025) per Business Quant data.